Teva and MedinCell Announce Positive Results for Registration Trial of Investigational Extended-Release Subcutaneous Injectable Risperidone for Patients with Schizophrenia | Business Wire
Risperidone Tabs 0.5mg #60
Teva's long-acting schizophrenia drug rejected by FDA -